SangStat Medical Corp.
- Share via
No one likes rejection, but SangStat Medical Corp. makes a business out of fighting it.
SangStat develops drugs and monitoring products to improve the results of organ transplants. Among them are drugs to promote the body’s acceptance of organs and to treat organ rejection.
The Menlo Park company is working on the launch of a generic version of cyclosporine and is expected to benefit from rulings by the Food and Drug Administration allowing wider use of the drug, which suppresses the immune system so a patient’s body doesn’t reject an implanted organ.
In February, the FDA approved the use of cyclosporine for treatment of arthritis.
SangStat is also seeking FDA approval of a drug called thymoglobulin to prevent rejection of transplanted kidneys as well as complications from bone marrow transplants.
SangStat recently said it expects to boost research spending in the next few years because it will be conducting additional clinical studies and expanding its sales and marketing teams.
The company’s stock is trading at about $18 on Nasdaq, about half its peak last year.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
